Biora Therapeutics to Speak at H.C. Wainwright 26th Global Investment Conference

SAN DIEGO, Aug. 26, 2024 — Biora Therapeutics, Inc. (Nasdaq: BIOR), a biotechnology company dedicated to transforming drug delivery, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, in New York, NY. Company representatives will engage in a presentation and one-on-one investor meetings on Wednesday, September 11, 2024, at 2:00 PM Eastern Time. The presentation can be viewed live via webcast, with a replay available on Biora’s website post-conference.

Biora Therapeutics is at the forefront of developing innovative therapeutic delivery systems, specifically focusing on two platforms: NaviCap™ and BioJet™. The NaviCap™ platform is designed for colon-targeted treatment of inflammatory bowel disease (IBD), aiming to enhance patient outcomes by delivering treatment directly to the affected area in the gastrointestinal tract. The BioJet™ platform offers a groundbreaking approach to oral delivery of large molecules, potentially replacing traditional needle-based injections. This platform is especially promising for chronic disease management, providing a needle-free, oral delivery method.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!